On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

In November 2023, Kostaive (ARCT-154), developed by Arcturus Therapeutics and CSL Behring, was the first samRNA vaccine to gain full marketing approval in Japan to treat Wuhan-Hu-1 strain SARS-Cov-2.

ARCT-2303 demonstrated superior immune response versus ARCT-154 as measured by neutralizing antibodies against Omicron XBB.1.5.6 in terms of geometric mean titer or GMT ratio and a seroconversion ...

ARCT-2303 demonstrated superior immune response versus ARCT-154 as measured by neutralizing antibodies against Omicron XBB.1.5.6 in terms of GMT ratio and SCR difference. Co-administration of ARCT ...

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh Chivukula ...

The study supports co-administration of KOSTAIVE with licensed influenza vaccines. ARCT-2303 demonstrated superior immune response versus ARCT-154 as measured by neutralizing antibodies against ...